Android app on Google Play

Avanir Pharmaceuticals (AVNR) Reports In-Line Q4 Loss of 9c/Share

December 12, 2012 4:02 PM EST Send to a Friend
Avanir Pharmaceuticals (NASDAQ: AVNR) reported Q4 EPS of ($0.09), in-line with the analyst estimate of ($0.09). Revenue for the quarter came in at $13.5 million versus the consensus estimate of $12.9 million.

For earnings history and earnings-related data on Avanir Pharmaceuticals (AVNR) click here.




You May Also Be Interested In


Related Categories

Earnings

Related Entities

Earnings

Add Your Comment